Based out of the Boston area, Dr. Dormitzer will start his role at GlaxoSmithKline on Dec. 3.
Dr. Dormitzer joins GlaxoSmithKline from Pfizer, where he served as vice president and chief scientific officer for viral vaccines and provided scientific leadership for the development of Pfizer’s COVID-19 vaccine.
“GSK has an industry-leading pipeline of vaccines, and Phil’s scientific expertise and significant experience with key innovative technologies, such as mRNA, structure-based antigen design and synthetic biology, will be key to ensuring we remain a leader in this field,” Hal Barron, MD, GlaxoSmithKline’s chief scientific officer and president of research and development, said in a news release.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
